Inter-organ communication: a gatekeeper for metabolic health

Judit Castillo-Armengol, Lluis Fajas* & Isabel C Lopez-Mejia**

Abstract

Multidirectional interactions between metabolic organs in the periphery and the central nervous system have evolved concomitantly with multicellular organisms to maintain whole-body energy homeostasis and ensure the organism’s adaptation to external cues. These interactions are altered in pathological conditions such as obesity and type 2 diabetes. Bioactive peptides and proteins, such as hormones and cytokines, produced by both peripheral organs and the central nervous system, are key messengers in this inter-organ communication. Despite the early discovery of the first hormones more than 100 years ago, recent studies taking advantage of novel technologies have shed light on the multiple ways used by cells in the body to communicate and maintain energy balance. This review briefly summarizes well-established concepts and focuses on recent advances describing how specific proteins and peptides mediate the crosstalk between gut, brain, and other peripheral metabolic organs in order to maintain energy homeostasis. Additionally, this review outlines how the improved knowledge about these inter-organ networks is helping us to redefine therapeutic strategies in an effort to promote healthy living and fight metabolic disorders and other diseases.

Keywords energy homeostasis; inter-organ communication; metabolism; obesity

DOI 10.15252/embr.201947903 | Received 11 February 2019 | Revised 21 May 2019 | Accepted 24 May 2019 | Published online 19 August 2019

EMBO Reports (2019) 20: e47903

See the Glossary for abbreviations used in this article.

Introduction

In order to maintain homeostasis and adapt to external conditions, the different tissues of multicellular organisms communicate with each other via multiple signals. Peripheral organs produce a plethora of bioactive molecules, including hormones (from the Greek horme that means impulsion), that ensure intercellular signaling in an autocrine, paracrine, or endocrine manner (see Glossary). Peripheral organs and immune cells can also produce smaller bioactive proteins, namely cytokines [1], that also participate in inter-organ communication. Alternatively, the nervous system coordinates whole-body metabolism not only by the production of neurohormones that act locally, but also by direct innervation of the target tissues [2–5]. Indeed, sympathetic and parasympathetic fibers innervating peripheral tissues express enzymes crucial for the biosynthesis and transport of specific molecules (neurotransmitters and neuropeptides) necessary for the tissue-specific response to external cues.

Early research from the 19th century, most notably from Claude Bernard, first suggested that a system involving chemical messengers ensures the communication between the different organs of the body [6]. The term “hormone” was first used in 1905 by the British physiologist Ernest Stalling to describe the gut hormone secretin, first described just 3 years prior [7,8]. Carl Ferdinand Cori and Gerty Cori then described the cycle in which lactate produced by anaerobic glycolysis in muscles can be recycled by the liver and converted to glucose. In turn, this glucose is returned to the muscle where it is metabolized to lactate [9]. This “Cori cycle” was one of the first described examples of an efficient communication system between organs, which functions to facilitate the metabolic adaptation to energy demands.

Key metabolic hormones, like pancreatic insulin and glucagon, were successfully identified, synthesized, and used for therapy in the course of the 20th century. The identification of signaling molecules produced by metabolic organs has increased exponentially in recent years, giving rise to the terms hepatokines [10], myokines [11], adipokines [12], and batokines [13], to describe the hormones produced by liver, muscle, white adipose tissue (WAT), and brown adipose tissue (BAT), respectively. The secretion of these signaling molecules varies according to the metabolic status of the body. They respond for instance to fasting and feeding cycles [14], to the circadian rhythm [15], to cold exposure [16], and to exercise[17], thus participating in the organism’s adaptive response and ensuring metabolic flexibility. Inter-organ communication is altered in different pathologic conditions, for example, in conditions related to adipose tissue dysfunction, like obesity. As such, alterations in hormones and cytokines are currently known to notably contribute to the spectrum of obesity-associated pathologies. Therefore, pharmacological interventions to modify the production of hormones/cytokines, or directly delivering recombinant hormones/cytokines, are currently being explored as promising approaches to treat a wide variety of obesity-related endocrine diseases. In this review, we summarize well-established mechanisms of inter-organ communication and focus on how recent research has highlighted the importance of the crosstalk
between gut, brain, and other specific peripheral metabolic organs, namely liver, muscle, WAT, BAT, and pancreas, in the maintenance of metabolic fitness. The role of the immune system in energy homeostasis has been recently discussed elsewhere [18] and is not discussed in this review. This review further concludes by citing additional actors and mediators of inter-organ communication and states our opinion about the future directions of the field.

### Glossary

| Acronym | Description |
|---------|-------------|
| ACC | Acetyl-CoA Carboxylase |
| ADRB3 | β3-adrenergic receptor |
| AdipoR1/2 | Adiponectin receptors |
| AgRP | Agouti-related peptide |
| AKT | Protein kinase B (PKB), also known as AKT |
| AMPK | AMP-activated protein kinase |
| Anorexigenic | Hormone(s) or compound(s) resulting in decreased appetite |
| ARC | Arcuate nucleus |
| ATP | Adenosine triphosphate |
| Autocrine signaling | signaling method in which a cell releases a signaling molecule that will bind to receptors and exert its action in the same cell. |
| BAs | Bile acids |
| BAT | Brown adipose tissue |
| BMP8b | Bone morphogenetic protein 8b |
| cAMP | Cyclic adenosine monophosphate |
| CCK | Cholecystokinin |
| CNS | Central nervous system |
| CSF | Cerebrospinal fluid |
| CTS8 | Cathepsin B |
| CX43 | Connexin 43 |
| CXC14 | C-X-C motif chemokine ligand-14 |
| Cytokines | class of small proteins that can be produced by a broad variety of cells and act as signaling molecules. In circulation, cytokines are usually found in smaller concentration than hormones. |
| DIO2 | Type 2 iodothyronine deiodinase |
| DIO | Diet-induced obesity |
| DMH | Dorsomedial hypothalamus |
| Endocrine | signaling method in which a cell releases a signaling molecule that will be released into the bloodstream before binding to receptors and exerting its action in distant cells. |
| Exosomes | extracellular vesicles that are released from cells. Exosomes constitute a system for intercellular communication and for the transmission of macromolecules between cells. Exosomes may contain a broad variety of cargo molecules like proteins, lipids, DNA, mRNAs and miRNAs. |
| FBN1 | Profibillin gene. Profibillin is the precursor of asprin. |
| FGF19 | Fibroblast growth factor 19 |
| FGF21 | Fibroblast growth factor 21 |
| FNDCS | Fibronectin type III domain-containing protein 5. FNDC5 is the precursor of irisin. |
| FoxO1 | Forkhead box protein 01 |
| GH | Growth hormone |
| GHSR | Growth hormone secretagogue receptor |
| GIP | Glucose-dependent insulinotropic peptide |
| GLP-1 | Glucagon-like peptide 1 |
| GLP-1R | GLP-1 receptors |
| GLUT2 | Glucose transporter 2 |
| HFD | High-fat diet |
| Hormones | class of proteins that act as signaling molecules. Hormones are secreted by a given tissue and are used to communicate between organs in order to trigger integrative responses to specific stimuli. |
| IL-1Ra | Interleukin 1 receptor antagonist |
| IL-6 | Interleukine 6 |
| IRS-2 | Insulin receptor substrate 2 |
| JAK2 | Janus kinase 2 |
| Lcn5 | Lipocalin 5 |
| LEAP2 | Liver-expressed antimicrobial peptide 2 |
| LepRb | Leptin receptor b |
| LHA | Lateral hypothalamic area |
| MAPK | Mitogen-activating protein kinase |
| MCP1 | Monocyte chemotactic protein 1 |
| Metn | Metein-like |
| mTOR | Mammalian target of rapamycin |
| NE | Norepinephrine |
| NPY | Neuropeptide Y |
| Orexigenic | Hormone(s) or compound(s) resulting in increased appetite. |
| Paracrine signaling | signaling method in which a cell releases a signaling molecule that will bind to receptors and exert its action in nearby cells. |
| PGC1α | Peroxisome proliferator-activated receptor gamma coactivator 1-α |
| PKA | Protein kinase A |
| PM20D1 | Peptidase M20 domain-containing 1 |
| POA | Preoptic area |
| POMC | Pro-opiomelanocortin |
| PSNS | Parasympathetic nervous system—The PSNS is part of the autonomic nervous system involved in the regulation of numerous basic body functions. It stimulates “feed and breed” and “rest and digest” functions and is antagonistic to the SNS. |
| RBP4 | Retinol binding protein 4 |
| RPA | Raphe pallidus |
| ScTr | Secretin receptor |
| SNS | Sympathetic nervous system—The SNS is part of the autonomic nervous system involved in “fight or flight” responses. It stimulates rapid and urgent reactions and is antagonistic to the PSNS. |
| STAT3 | Signal transducer and activator of transcription 3 |
| T2D | Type 2 diabetes |
| T3, T4 | Thyroid hormones |
| TCTP | T-cell protein tyrosine phosphatase |
| TGFb | Transforming growth factor β |
| TGR5 | BA receptor |
| TG | Triglycerides |
| TNF-α | Tumor necrosis factor-α |
| TSH | Thyroid-stimulating hormone |
| UCP1 | Uncoupling protein 1 |
| VAN | Vagal afferent neurons |
| VMH | Ventromedial hypothalamus |
| WAT | White adipose tissue |

### Inter-organ communication in the control of fasting/feeding cycles

In this section, we will first discuss the organismal adaptation to the consumption of food (Fig 1), followed by the compensatory response engaged in energy low conditions like the fasting state (Fig 2).
Inter-organ communication in feeding conditions

The physiological response to a meal ingestion initiates in the gut and is triggered by the presence of nutrients. Enteroendocrine cells sense nutrients in the intestinal lumen and produce peptides such as cholecystokinin (CCK), secretin, and the incretins; glucose-dependent insulinotropic peptide (GIP); and glucagon-like peptide 1 (GLP-1) [19,20]. Gut hormones play their role by directly acting on target tissues via the circulation or by activating intestinal neurons in a paracrine manner. A major target for gut-derived hormones is the vagal afferent neurons (VANs) [21]. Endogenous GLP-1 acts on VANs to inhibit food intake. The actions of GLP-1 are further modulated by the fact that GLP-1 receptors (GLP-1R) are internalized upon fasting conditions, but translocate to the plasma membrane after a meal when ghrelin levels are low. GLP-1 and GIP work synergistically to potentiate glucose-stimulated insulin secretion by pancreatic β-cells [21]. Moreover, GLP-1 inhibits glucagon production by pancreatic α-cells. Secretin stimulates exocrine pancreas activity to ensure a proper environment for digestion and absorption of nutrients. Moreover, secretin can also inhibit food intake via the activation of secretin receptor (SctR) in vagal sensory nerves and melanocortin signaling in the brain [22,23].

After the postprandial regulation initiated in the gut, changes in circulating levels of nutrients, mainly glucose and triglycerides (TG), also engage the response of several peripheral organs and the nervous system. An increase in circulating glucose levels is sensed by pancreatic β-cells through the glucose transporter GLUT2. Glucose sensing leads to a β-cell response that ultimately leads to insulin secretion [24]. In parallel, glucose inhibits the release of glucagon from the pancreatic α-cells [25,26]. Insulin targets insulin-sensitive organs, like the liver, muscle, WAT, and brain to induce glucose utilization and storage thus preventing hyperglycemia. By signaling through the brain, insulin regulates feeding behavior and modifies energy metabolism in liver and adipose tissues, as well as several more cognitive functions [27–31]. In the liver, insulin promotes metabolism of glucose by hexokinases and de novo lipogenesis, while decreasing hepatic glucose production. Intact hepatic insulin signaling is, however, dispensable for the postprandial repression of hepatic glucose production in the absence of hepatic FoxO1 [32,33], highlighting the importance of hypothalamic insulin signaling in the
control of liver glucose metabolism [34]. Insulin also triggers glucose uptake by promoting the externalization of the glucose transporter GLUT4 in WAT and muscle, glycogen synthesis in muscle, and de novo lipogenesis by promoting the expression and activity of fatty acid synthesis enzymes specifically in WAT. In WAT, glucose-derived glycerol serves as building blocks for TGs; in turn, TGs serve as a fuel stock for conditions of energy scarcity. In order to avoid excessive food intake, excessive adiposity, and unnecessary energy storage, which have deleterious effects for the organism, WAT also has the capability to act as a hormone-producing organ. Leptin is secreted by white adipocytes proportionally to TG stores [35–37]. Leptin is widely known to target the central nervous system that highly expresses the long form of leptin receptor (LepRb). By binding LepRb and signaling via JAK2 and STAT3 in the brain, leptin signals to maintain a constant energy stock. In order to avoid excessive food intake, excessive adiposity, and unnecessary energy storage, which have deleterious effects for the organism, WAT also has the capability to act as a hormone-producing organ. Leptin is secreted by white adipocytes proportionally to TG stores [35–37]. Leptin is widely known to target the central nervous system that highly expresses the long form of leptin receptor (LepRb). By binding LepRb and signaling via JAK2 and STAT3 in the brain, leptin signals to maintain a constant energy stock. Indeed, leptin suppresses food intake and the production of adrenal corticosteroids while promoting energy expenditure and decreasing insulin secretion [38,39]. Leptin can also activate glucose uptake in BAT, as well as glucose uptake and fatty acid oxidation in muscle in an AMPK-dependent manner [40]. Whether this process is direct or indirect remains unclear [41].

In feeding conditions, the bile acids (BAs) released into the intestinal lumen also induce the expression of FGF19 (Fgf15 in mice) in the ileum. FGF19 then signals to the liver and induces a feedback repression of hepatic BA synthesis [42]. FGF19 also increases liver protein and glycogen synthesis while repressing hepatic glucose production [43,44], in order to ensure proper post-prandial energy storage independently from insulin. Importantly, Fgf15 can also signal through the brain to modulate glucose homeostasis [45] and glucagon secretion [46].

More recently, the liver-expressed antimicrobial peptide 2 (LEAP2), a peptide initially described as an antimicrobial liver-produced peptide, was also described to be a gut-derived peptide. LEAP2 is produced by the liver and the small intestine in the fed state, and its secretion is suppressed by fasting. Importantly, LEAP2 was reported to be an endogenous antagonist of the ghrelin receptor, or growth hormone secretagogue receptor (GHSR). Indeed, LEAP2 can fully blunt GHSR activation by ghrelin, thus reducing food intake and growth hormone (GH) release [47]. This recent study adds LEAP2 to the growing list of hormones that connect gut, brain, and other peripheral organs in metabolic control.
Thus far, we have described how several organs from the body, mainly gut, brain, pancreas, and WAT communicate in the fed state. Upon ingestion of a meal, the aforementioned organs orchestrate a coordinated response in order to ensure proper digestion and storage of energy substrates, while initiating a negative feedback loop involving satiety and increased energy expenditure to maintain energy homeostasis by preventing an excessive “positive energy balance” (Fig 1).

**Inter-organ communication in fasting conditions**

When the organism’s energy levels are low, the lack of food in the stomach, as well as the decrease in blood glucose, are sensed in order to replenish energy stores and to produce alternative substrates to keep organs functioning. Ghrelin is mainly secreted by the gastric epithelium when the stomach is empty. Plasma concentrations of ghrelin are high during fasting and decrease in the postprandial state [48]. Ghrelin was first described as a potent inducer of GH secretion [49], but it is now known to stimulate food intake and adiposity and to maintain glucose levels by binding to its receptor GHSR. Ghrelin exerts its orexigenic effects centrally in the arcuate nucleus (ARC) of the hypothalamus by triggering the expression of agouti-related protein (AgRP) and neuropeptide Y (NPY) in order to increase appetite. However, the exact mechanism by which ghrelin plays its central role remains unclear. To date, three hypotheses have been suggested as follows: (i) Ghrelin acts by activating VANS, (ii) ghrelin is synthesized locally in response to feeding, and (iii) ghrelin crosses the blood–brain barrier and activates its receptor in the hypothalamus [50]. Ghrelin attenuates insulin production and increases blood glucose concentration by promoting the intracellular localization of the pancreatic β-cell GLP-1R under fasting conditions, thus counteracting GLP-1 signaling [21]. Ghrelin also stimulates glucagon secretion in pancreatic α-cells [51]. Moreover, ghrelin can directly promote adiposity, independently of food intake or GH secretion, by increasing carbohydrate use, stimulating lipid synthesis, and reducing fatty acid oxidation [50,52]. The effects of ghrelin on adiposity have been shown to require intact sympathetic nervous system signaling [53].

Adipokine secretion is also modified in low energy conditions. Leptin circulating levels rapidly decrease upon fasting. This reduction in leptin promotes a switch between the “fasted state” and the “fed state” by promoting food intake and reducing energy expenditure [54]. In contrast to leptin, adiponectin levels increase in low glucose and low insulin conditions, at least in the cerebrospinal fluid (CSF) [55,56]. Overall, adiponectin levels are inversely proportional to adiposity and correlate with improved metabolic fitness. Numerous studies have reported that adiponectin targets numerous tissues (adiponectin receptors AdipoR1/2 are essentially ubiquitous). In the brain, adiponectin activates AMPK signaling in hypothalamic ARC, resulting in an increase in food intake and a reduction in energy expenditure, suggesting that in the hypothalamus adiponectin promotes feeding and inhibits the anorexigenic effects of leptin [55,56]. In the peripheral tissues, adiponectin promotes liver insulin sensitivity via several independent mechanisms: an AMPK-dependent mechanism involving increased ACC phosphorylation, an AMPK-independent mechanism that involves a reduction in liver ceramide levels [57], and an IL-6-dependent mechanism that involves the upregulation of insulin receptor substrate 2 (IRS-2) through the activation of STAT3 [58]. Adiponectin also reduces hepatic de novo lipid synthesis and increases hepatic fatty acid oxidation [39] but its effects in hepatic glucose production remain debated [39].

Asprosin, a novel fasting-induced adipokine that promotes hepatic glucose production, was recently identified [59]. Asprosin is the C-terminal cleavage product of profibillin (FBN1 gene). It is encoded by the last two exons of FBN1 and is mainly produced by adipose tissue in mice. Asprosin directly targets the liver to promote glucose release, without increasing plasma levels of glucagon, catecholamines, and glucocorticoids. This process is independent from glucagon receptor signaling and from the β-adrenergic receptor [59]. Additionally, asprosin can directly target the central nervous system (CNS) to increase food intake [60].

Fibroblast growth factor 21 (FGF21) was first identified as an hepatokine [61] and has been shown to be necessary for the adaptation to fasting [62,63]. Indeed, liver expression and plasma levels of FGF21 are increased upon fasting. FGF21 in turn increases adipose tissue lipolysis, as well as hepatic fatty acid oxidation and ketogenesis, thus ensuring the availability of substrates for the brain. It is worth noting that FGF21 knockout mice exhibit lower glycemia in the fasted state, and lower plasma levels of ketone bodies in both the fasted and the fed state [64,65].

Fasting-induced hypoglycemia also results in the stimulated secretion of glucagon. Hypoglycemia is directly sensed by GLUT2-positive hypothalamic neurons that promote glucagon secretion via an increase in parasympathetic input [66]. Glucagon signals to the liver through the PKA signaling pathway to stimulate (i) the mobilization of hepatic glycogen (glycogenolysis) and, if the fasting is prolonged, (ii) hepatic de novo glucose synthesis (gluconeogenesis), and (iii) to repress glycolysis and gluconeogenesis. To ensure the availability of alternative substrates for the peripheral organs, and to preserve glucose production for the brain, glucagon also triggers lipolysis in WAT. TGs are metabolized into free fatty acids and glycerol. Glycerol is transported to the liver where it is oxidized or used as a substrate for gluconeogenesis. Albumin-bound fatty acids are transported in the bloodstream to serve as oxidation substrates for the liver, muscle, and other tissues. WAT lipolysis can also directly be promoted by sympathetic nervous system (SNS) innervation. Indeed, SNS fibers can release norepinephrine (NE) locally and exert similar effects to glucagon. This increased SNS tone in WAT could be directly triggered by hypoglycemia sensing in the brain [67,68]. Notably, direct innervation of WAT depots is sparser than in BAT [69]. However, it is denser in specific regions of subcutaneous (or inguinal) WAT and can be increased in response to cold [70,71]. Therefore, cell-to-cell communication via connexin 43 (CX43) containing gap junctions is essential to disseminating adrenergic activation signals [72].

In this section, we described inter-organ communication in situations of food deprivation (Fig 2). This counter regulatory response promotes food intake, maintains blood glucose levels high enough to prevent alterations in brain function, and ensures that energy-providing substrates are available to all organs. This is accompanied by an overall reduction of energy expenditure in order to preserve energy.

**Inter-organ communication in non-shivering thermogenesis**

In order to adapt to cold exposure and maintain body temperature, different strategies have been developed by homeotherms. Mammals have BAT, a highly specialized tissue that functions to produce heat...
BAT is especially abundant in hibernating mammals [74], but can also be found in adult humans [75]. Inter-organ communication in response to cold stress is summarized in Fig 3.

**Cold-induced thermogenesis**

The main organ that integrates the response to cold is the CNS. Cold is sensed by the terminals of sensory neurons found in skin, and this signal is then processed in the hypothalamic preoptic area (POA), also known as the thermoregulatory center [76]. The transduction of the signal will stimulate other hypothalamic regions, namely the lateral hypothalamic area (LHA), the ventromedial hypothalamus (VMH), the dorsomedial hypothalamus (DMH), and the arcuate nucleus (ARC).

Orexin producing neurons that are located in the LHA, named orexin neurons, participate in the regulation of thermogenesis. The central administration of orexin peptide has been described to stimulate BAT activation and therefore thermogenesis [77]. Moreover, orexin infusion into the VMH can stimulate the sympathetic firing in BAT [78]. Both the LHA and the VMH can synergistically interact and activate BAT. Hypothalamic expression of bone morphogenetic protein 8b (BMP8b) in the VMH stimulates orexin secretion in the LHA through a decrease in AMPK activity and thus enhances the firing of projections that will stimulate BAT thermogenesis [79]. Interestingly, BMP8b can also be produced in BAT and promote NE signaling locally, activating the MAPK pathway and lipolysis in brown adipocytes [80].

Several studies have linked the DMH with the response to cold. For example, a chemical stimulation of this area increases the thermogenic response in rats [81]. Similarly, administration of the incretin hormone GLP-1 in the DMH increases BAT thermogenesis [82]. Outflow from these areas is triggered by the premotor neurons found in the brain stem region raphe pallidus (RPA). It has been broadly discussed that sympathetic nerves are present within the parenchyma of adipose tissue [83]. These nerves express tyrosine

---

**Figure 3. Inter-organ communication under cold exposure.**

Cold stimuli, sensed by neurons in the skin, activate the thermoregulatory hypothalamic regions of the brain that will secrete orexin and BMP8b to stimulate BAT thermogenesis. Moreover, the SNS is responsible for the local production of NE in BAT. The hypothalamic–pituitary–thyroid axis is also activated in response to cold and promotes the release of thyroid hormones (T3 and T4) in order to contribute to the activation of BAT thermogenesis. Cold exposure can also trigger muscle shivering and thus the production of the myokine irisin. Irisin can in turn stimulate BAT thermogenesis. If cold exposure is sustained over time, WAT undergoes browning and can contribute to thermogenesis. Irisin is one of the molecules that can trigger this process. In addition, cold-dependent hepatic FGF21 and BA secretion contribute to the browning of WAT. Finally, FGF21 can be produced by WAT, and BMP8b and FGF21 can be produced by BAT, after cold activation and promote thermogenesis in a paracrine manner.

© 2019 The Authors
hydroxylase, the enzyme responsible for the secretion of the catecholamine hormone NE [84]. BAT is a major catecholamine-responsive tissue. It is mainly constituted by brown adipocytes that contain numerous lipid droplets and a high number of mitochondria. NE stimulates the β3-adrenergic receptor (ADBR3) and activates the cAMP/PKA pathway, thus triggering lipolysis and increasing the expression of uncoupling protein 1 (UCP1). Free fatty acids, resulting from lipolysis, are used both as energy substrates and as activators of UCP1 to uncouple ATP production from mitochondrial respiration into heat [73,85].

Apart from catecholamines, thyroid hormones can also trigger BAT activity [86]. The thyroid hormones T3 and T4 are synthesized in the thyroid gland upon hypothalamic stimulation of the pituitary gland and thyroid-stimulating hormone (TSH) production [87]. Thyroid hormones access brown adipocytes from the bloodstream through specific transporters. In brown adipocytes, T4 can be converted to its active form T3 via type 2 iodothyronine deiodinase (DIO2) thus compensating for the low levels of thyroid gland-secreted T3 [88]. T3 directly activates lipolysis through the PKA pathway. The relevance of thyroid hormone regulation for BAT function is illustrated by the blunted thermogenic response observed in DIO2 knockout mice, despite their increased UCP1 expression [89].

If cold stress is sustained over time, a process known as browning is triggered. This process is characterized by the appearance of brite (from brown-in-white) adipocytes, also called beige adipocytes, mainly in subcutaneous VAT. Brite adipocytes can express UCP1 and, as such, can participate in the maintenance of body temperature [90]. UCP1-expressing adipocytes (brown and brite) are also capable of participating in the regulation of glucose homeostasis due to their high capability to uptake glucose. Moreover, they can contribute significantly to the clearance of circulating lipids, increasing insulin sensitivity. Their potential contribution to global energy expenditure has opened the door to new therapeutic strategies against obesity and diabetes.

Under cold exposure, FGF21 can be secreted by BAT and VAT, have a paracrine effect, and stimulate the expression of thermogenic genes [91]. Some teams have reported that FGF21 knockout mice have impaired adaptation to chronic cold exposure and decreased browning of VAT [92]. However, others have shown that the lack of FGF21 in long-term cold adaptation does not impair the thermogenic response of mice [93]. Despite the evidence of FGF21 production in VAT, controversial results were published by Véniant et al [94] who demonstrated that beneficial effects of weight loss observed after cold were not directly related to FGF21-induced browning. Additionally, hepatic FGF21 production can also be induced by cold, and blunted hepatic FGF21 secretion, but not adipocytic FGF21 secretion, results in impaired cold tolerance and decreased sympathetic nerve activity in BAT [95]. Therefore, further studies are needed to elucidate the role of FGF21 in the control of non-shivering thermogenesis.

Besides their role in the digestion of dietary lipids, hepatic BAs can be induced by cold exposure [96]. It has been demonstrated that BA secretion increases energy expenditure in BAT by enhancing the enzymatic activity of DIO2 and therefore regulating thyroid hormone metabolism in BAT [97]. Moreover, studies using BA receptor TGR5 adipose tissue-specific knockout mice proved that BAs also participate in the browning of VAT. These mice show negligible browning and exhibit reduced cold tolerance due to reduced adipose mitochondrial fusion [98].

Historically, UCP1 has been considered indispensable for thermogenesis in BAT. However, recent research demonstrates that UCP1 is not essential for non-shivering thermogenesis [93,99,100]. Peptidase M20 domain-containing 1 (PM2OD1), a secreted enzyme produced by brown and brite adipocytes, has been recently discovered to contribute to this alternative thermogenesis by participating in the uncoupling of mitochondria in an UCP1-independent manner [99,100].

**Feeding-induced thermogenesis**

Cold is not the only stimulus that activates non-shivering thermogenesis. It has been demonstrated by several groups that there is a meal-associated thermogenesis [101–103]. The activation of feeding-responsive thermogenesis has been strongly associated with food intake regulation by inhibiting orexigenic activation in the brain, revealing a gut–brain–BAT–brain axis [104]. In particular, feeding activates the secretion of periprandial gut hormones, such as CCK, GLP-1, and secretin [105–107]. Most of these molecules act through the brain, like GLP-1 and CCK, where they increase sympathetic activation and therefore stimulate the local release of NE in BAT. Interestingly, secretin can stimulate BAT thermogenesis in a non-sympathetic manner and contribute to satiation. A secretin injection in fasted mice directly activates BAT thermogenesis by increasing lipolysis through the cAMP-PKA pathway. Moreover, secretin treatment increases the expression of the anorexigenic pro-opiomelanocortin (POMC) peptide in the hypothalamus and therefore reduces food intake [107].

Apart from its role in the regulation of food intake described above, leptin can increase energy expenditure by inducing BAT activation. The actions of leptin and insulin in POMC neurons can also be triggered by a decrease in the hypothalamic levels of T-cell protein tyrosine phosphatase (TCPTP), which is a negative regulator of insulin signaling, to further increase the browning of VAT and energy expenditure [108,109]. This mechanism can limit the effects of diet-induced obesity (DIO).

In this section, we described how brown and beige adipose tissue thermogenesis are activated not only to adapt to cold stress (Fig 3), but also to prevent the excessive energy storage that could lead to obesity and thus maintain general energy homeostasis in the organism.

**Inter-organ communication during exercise**

Physical exercise was first described to have beneficial effects for health in 450 BC by Hippocrates [110]. Despite early hypotheses suggesting that muscles release a hypoglycemic “humoral factor” in response to glucose demand [111], part of the molecular mechanisms behind this observation have only been described rather recently. Indeed, physical exercise is not only beneficial because of the immediate increase in energy expenditure; it also remodels whole-body energy metabolism. The ensemble of muscle-derived peptides and proteins, currently referred to as myokines, is at least in part, responsible for exercise whole-body health benefits. Recent analyses of muscle secretomes revealed that aerobic exercise or strength training trigger the secretion of numerous myokines [11].
Importantly, it is worth noting that the production of “positive” myokines is as much promoted by physical exercise as it is repressed by physical inactivity, highlighting the importance of lifestyle for healthspan [112].

More precisely, during exercise skeletal muscle tightly interacts with adipose tissue, pancreas, and liver to sustain the energy demands of physical activity and mediate positive effects in whole-body energy metabolism. The first exercise-induced myokine to be described was interleukin 6 (IL-6) [113]. Exercise-induced IL-6 production was initially believed to be linked to muscle damage, but has now been proven to directly depend on contraction and to mediate muscle glucose uptake, increased insulin sensitivity, and increased fatty acid oxidation. IL-6 also triggers insulin production in pancreas, hepatic glucose production, and adipose tissue lipolysis, thus ensuring the availability of energy substrates for exercising muscle [11,17]. Moreover, IL-6 has the ability to induce an anti-inflammatory response by reducing tumor necrosis factor-α (TNF-α) production while increasing the levels of interleukin 10 (IL-10), interleukin 1 receptor antagonist (IL-1Ra), and interleukin 15 (IL-15) [17,114]. Future studies using tissue-specific IL-6 knockout mice will be required, however, to fully elucidate to what extent muscle IL-6 contributes to the positive effects of exercise and to determine whether the anti-inflammatory effects of IL-6 are muscle-cell autonomous or not [11,114].

Irisin, a cleavage product of the protein encoded by the FNDC5 gene, is an exercise-dependent myokine that was first described in 2012 by Bostrom and colleagues [115]. Irisin was shown to trigger WAT remodeling by increasing p38 signaling, UCP1 expression, and therefore browning [115,116]. Irisin can also increase muscle oxidative metabolism and substrate (glucose and fatty acid) uptake, and reduce hepatic glucose output [117]. Interestingly, cold-induced muscle shivering can increase circulating irisin levels and promote brown fat thermogenesis [118] (Fig 3). Moreover, irisin of central (hippocampal) and peripheral origin has been recently shown to promote an increase in cognitive function [119], further highlighting the potential benefits of exercise on healthspan.

Some groups have suggested that irisin can also be produced and secreted by adipose tissue and liver [120]. Nevertheless, some inconsistencies have been found between human and mice and in the methodology used [121], which adds more complexity to the functions of irisin in energy homeostasis. In addition, FGF21 has also been proposed to be produced by skeletal muscle in response to the PI3K-AKT pathway and to act in an autocrine manner to reduce muscle insulin resistance. Moreover, under cold exposure, when shivering thermogenesis is induced, FGF21 can synergize with irisin to promote BAT non-shivering thermogenesis [118].

Finally, a recent study using proteomic approaches demonstrates that the secreted form of lysosomal enzyme cathepsin B (CTSB) is also an exercise-responsive myokine that targets the brain, promotes hippocampal neurogenesis, and therefore enhances cognitive abilities [122].

Overall in this section, we described how, in order to satisfy the energy demands generated by exercise, muscle communicates with other organs to ensure energy substrate availability. Moreover, physical exercise also promotes the browning of WAT and BAT thermogenesis, possibly in order to meet the increased demand for fatty acid and glucose oxidation and to prevent the accumulation of energy substrates in the circulation [123,124]. Importantly, during exercise, muscle can signal directly to the brain to promote cognitive function, providing an additional support for lifestyle modifications including an increase in physical activity [125].

Inter-organ communication in pathological conditions: the case of obesity and related disorders

In pathological situations, WAT can account for more than 50% of human body weight. The increasing prevalence of obesity has triggered considerable interest in understanding the physiological mechanisms promoting calorie storage, and energy expenditure, in order to prevent the deleterious metabolic consequences of obesity such as hyperglycemia, insulin resistance, dyslipidemia, and hepatic steatosis. Insulin resistance is characterized by a decrease in insulin-stimulated glucose uptake in adipocytes and muscle cells, as well as by a blunted insulin-stimulated repression of hepatic glucose production [126]. Most humans with obesity, as well as DIO mice, fed highly caloric palatable diets, develop insulin resistance, and exhibit high plasma levels of leptin [35]. Despite this, they do not show the expected reduction in food intake and increase in energy expenditure, thus leading to the concept of leptin resistance, probably due to a decrease in JAK2-STAT3 signaling in pathologic conditions [127]. In obesity conditions, pathological leptin signaling also contributes to sustained hepatic glucose production, due to abnormal activation of ARC neurons [128]. Obesity is also accompanied by an increased NPY expression in the ARC. This increase triggers a reduction in the expression of tyrosine hydroxylase neurons in the paraventricular nucleus (PVN) of the hypothalamus and consequently, diminishes the thermogenic activation of BAT and overall energy expenditure [129]. Circulating asprosin levels are higher in obese humans and mice [60]. Due to the orexigenic effects of this hormone, this alteration could contribute to the difficulties to obtain a voluntary reduction in food intake in obese patients [60].

Alternatively, mouse models of obesity and unhealthy obese individuals exhibit lower circulating levels of adiponectin. This finding that adiponectin levels are proportional to metabolic fitness has prompted the use of recombinant adiponectin and other adiponectin receptor agonists in several mouse models of obesity. So far, the activation of adiponectin signaling has improved glucose tolerance, insulin sensitivity, and longevity in mice [12,130]. Importantly, adiponectin has been shown to improve the metabolic profile in leptin deficient ob/ob mice by overall increasing energy expenditure, despite not triggering a reduction in food intake [131]. In pathological conditions of obesity, the reduction in CSF levels of adiponectin that is accompanied by feeding is lost, thus maintaining a “high food intake behavior” even in conditions that are not of energy scarcity (high energy conditions) [56]. As mentioned above, the levels of the gluconeogenic adipokine asprosin are elevated in obese mice. This observation suggests that high plasma asprosin may contribute to the onset of hyperglycemia and insulin resistance in mice and humans. Moreover, the improvement of the metabolic phenotype of obese insulin-resistant mice when using an antibody to sequester circulating asprosin makes this novel adipokine a potential therapeutic target against diabetes [59].

Interestingly, some studies suggest that the beneficial effects of FGF21 in glucose homeostasis are at least partially mediated by an
increase in adiponectin production by WAT [132]. However, other groups show that adiponectin is dispensable for the metabolic effects of FGF21 [133]. Moreover, despite evidence showing improved metabolic fitness in FGF21 treatment or overexpression studies, clinical studies in humans have revealed high FGF21 circulating concentrations in obese and insulin-resistant subjects, as well as the onset of so called “FGF21 resistance” [134]. These findings highlight the fact that the importance of FGF21 in metabolic health is still debated.

An example of the use of novel strategies for the discovery of endocrine interactions with physiological relevance for whole-body metabolism is the recent discovery of a novel adipokine, mouse lipocalin 5 (Lcn5; LCN6 in humans), that has the ability to promote insulin sensitivity by enhancing muscle mitochondrial function [135]. Seldin and colleagues developed a bioinformatic framework that takes advantage of publicly available data generated with different OMICS approaches to identify new circuits of inter-organ communication, thus contributing to our understanding of the mechanism by which WAT communicates with other organs to maintain homeostasis. Of note, despite showing significant effects in promoting muscle mitochondrial function in cellular models, the effects of the novel adipokine Lcn5 in promoting glucose and insulin sensitivity in vivo were more pronounced in a high-fat high-sucrose (HF-HS) model. However, it is worth noting that Lcn5 over-expression had positive effects on the metabolic status whether at the beginning or after several weeks of HF-HS diet [135]. The use of unbiased genetic and proteomic approaches also allowed the identification of a novel secreted protein, Meteorin-like (Metrnl), that can be produced by exercising muscle and cold exposed adipose tissue. Metrnl promotes adipose tissue browning by recruiting IL-6 and IL-13 producing eosinophils and thus promoting anti-inflammatory macrophage activation [136]. However, serum Metrnl levels are decreased in patients with T2D and inversely correlate with fasting glucose levels [137]. These findings highlight the fact that improving muscle oxidative capacity is beneficial both to prevent metabolic disease and to cure metabolic disease; however, the role of Lcn5 and Metrnl in normal physiology remains to be determined.

The effect of gut hormones is also altered in obesity. Indeed, ghrelin has lower orexigenic activity in DIO rodents due to a reduction in activation and plasticity of NPY/AgRP neurons [138]. Moreover, a reduced incretin effect is seen in subjects with type 2 diabetes (T2D) and obesity. Interestingly, postprandial glucagon-like peptide-1 (GLP-1) secretion is increased in obese patients following bariatric surgery and correlates with weight loss maintenance [139].

Despite the positive effects of muscle-derived IL-6 that are mentioned in the previous section, deleterious IL-6 can also be released by adipose tissue. Chronically, high levels of circulating IL-6 in response to HFD contribute to obesity by promoting macrophage recruitment to WAT [140]. In conditions of insulin resistance, WAT secretome is substantially altered and includes a broad range of proinflammatory factors, such as TNF-α, IL-6, interleukin 8 (IL-8), and interleukin 1β (IL-1B) and monococyte chemotactic protein 1 (MCP1) [12]. The secretion of these proinflammatory cytokines and chemokines, as well as the secretion of other adipokines like retinol binding protein 4 (RBP4) [141,142], is now well admitted to contribute to the onset of the physiological alterations accompanying obesity [12].

Physical inactivity, that can be both a cause and a consequence of obesity, is known to be associated with decreased insulin sensitivity, reduced postprandial lipid metabolism, decreased muscle mass, and obesity. Alterations in myokine production associated with physical inactivity may also mediate the onset of obesity. This may be the case for myostatin (also known as GDF8), a member of the TGF-β superfamily. Myostatin was first described to be secreted during development to limit muscle growth [143], but is also known today to be produced in adults [144], and to promote muscle atrophy, in part by inhibiting AKT and mTOR signaling. Importantly, the inhibition of myostatin signaling increases PGC1α and mitochondrial biogenesis [145], while mice deficient for myostatin show an improved metabolic phenotype and a resistance to HFD [146,147]. However, myostatin-deficient mice also develop insulin resistance via alterations in AMPK activity [148], highlighting the need to determine the exact effects of myostatin signaling, as well as of other myokines correlating with obesity, in whole-body energy homeostasis [112].

Overall, the finding that inter-organ communication is altered in conditions of obesity (Table 1) has gathered increasing attention for researchers aiming to manipulate those preestablished axes to counteract metabolic alterations.

Taking advantage of inter-organ communication to treat obesity and associated diseases

Understanding the biological networks that are involved in the induction of energy expenditure and promote satiety is crucial to target metabolic organs to increase weight loss in the context of the current obesity epidemic. Therefore, numerous efforts are currently being made to further understand the role of the signaling molecules described in this review and to identify novel mechanisms of inter-organ communication that could contribute to the establishment of new therapeutic approaches against obesity and diabetes. Efforts to include recombinant adipokines or adipokine analogs as pharmacotherapy against obesity began more than 20 years ago. However, most of these efforts have not yet obtained significant success. Indeed, leptin therapy alone has failed to induce significant weight loss or insulin sensitization [149,150]. However, the use of leptin analogs in combination with other agents, namely amylin, has given more encouraging results, but was stopped due to adverse secondary effects [12]. Importantly, despite apparently promoting hepatic glucose output by increasing the availability of gluconeogenic substrates in the presence of insulin, in conditions in which insulin levels are low, like in T2D, leptin inhibits lipolysis thus decreasing the circulating levels of gluconeogenic substrates such as glycerol, fatty acids, and ketone bodies, which may play a role in suppressing gluconeogenesis under leptin therapy [41]. Adiponectin receptor analogs have successfully been used in preclinical mouse models [130], but have not yet been used in human patients. A truncated globular form of adiponectin has also been shown to promote muscle fatty acid oxidation, decrease muscle ceramides, and overall improve insulin sensitivity, whether or not this globular adiponectin mimics the function of the multimeric adiponectin complexes found in circulation remains to be demonstrated [39]. More recently, a neutralizing antibody against asprosin was used in obese mice to reduce appetite, body weight,
and blood glucose, suggesting that this orexigenic hormone can be targeted to modulate food intake and lower glycemia in obese subjects [60].

Due to the potential therapeutic effect of increasing overall energy consumption by promoting brite and brown adipose cell metabolism, recent research has focused on the identification of natural hormones or compounds with the capability to promote thermogenic function, such as FGF21, irisin, and BAs [151]. Extensive efforts have also been made with the use of recombinant FGF21 or FGF21 variants as potential therapy, due to beneficial metabolic effects observed in mice [152,153]; however, only a small trend toward glucose lowering was reported in humans [154]. Moreover, there is increased concern about the use of FGF21 in therapy due to potential adverse effects on the skeletal system, more specifically in bones [155,156]. Finally, despite evidence that irisin treatment can positively affect glucose and lipid metabolism in mice, no real consensus exists as of yet concerning the link between irisin and the metabolic syndrome in humans, and no irisin analog has been used for studies in humans [117].

Significant preclinical and clinical success, however, has been encountered by using GLP-1 receptor agonists (GLP-1Ras), that trigger a reduction in body weight by promoting satiety and reducing food intake, and profit from a longer half-life than endogenous GLP-1. Moreover, GLP-1Ras improve glycemic control and reduce liver inflammation and fibrosis [157]. More recently, GLP-1 and glucagon receptor co-agonists have been successfully used in preclinical studies for metabolic diseases [158], but additional research is necessary to demonstrate their efficacy in humans.

As of now, most potential therapies that take advantage of inter-organ communication for the treatment of metabolic syndromes remain based on lifestyle alterations: increased physical activity and decreased energy intake.

### Concluding remarks

There is still much work to be done to understand the complex inter-organ networks that are needed to coordinate energy homeostasis. Recent studies show that more than 15% of the protein-coding genome encodes for roughly 3,000 secreted proteins, but only a handful of them has been properly annotated [159,160], suggesting that a very high number of “molecular messengers” remain to be discovered. More recently, population-based methods taking advantage of the natural variations between transcript levels within strains of a mouse reference population have been used to identify new inter-organ communication networks in metabolism [135]. This bioinformatic-based approach allowed for the identification of Lcn5, an adipokine that promotes muscle mitochondrial function, and of Notum, a hepatokine that promotes WAT browning [135].

Moreover, the analysis of large datasets generated with metabolomics and lipidomics studies has shown that different kinds of metabolites, like lipids, amino acids, ketone bodies, and BAs can

### Table 1. Alterations of inter-organ communication in obesity.

| Molecule | Situation in pathophysiological conditions | References |
|----------|-------------------------------------------|------------|
| Leptin   | Leptin resistance in DIO mice or obese humans | [127] |
| NPY      | NPY expression is increased in obesity and leads to decreased BAT thermogenesis and increased food intake | [129] |
| Adiponectin | Adiponectin secretion is diminished in obese mice and unhealthy obese humans, thus impairing glucose tolerance and insulin sensitivity | [12,130,133] |
| FGF21    | Increased FGF21 levels are found in obese individuals, even though an increase in FGF21 is usually associated with metabolic fitness | [134,153] |
| Asprosin | Obese mice and humans have increased asprosin levels, associated with hyperglycemia, insulin resistance and increased appetite | [60] |
| Lcn5     | Increasing Lcn5 (LCN6 in humans) levels promotes insulin sensitivity by enhancing muscle function in murine DIO models | [135] |
| Metrnl   | Circulating Meteorin-like levels are significantly lower in T2D patients. Serum Metrnl is inversely correlated with fasting glucose in humans. Accordingly, in mice, Metrnl has been found to stimulate energy expenditure and WAT browning | [136,137] |
| Ghrelin  | In DIO mice, increased levels of ghrelin do not reduce food intake, due to an impaired downstream activation of neurons. This is defined as ghrelin resistance | [138] |
| GLP-1    | GLP-1 secretion is higher after bariatric surgery and is associated with the important decrease in body weight that accompanies this intervention | [139] |
| IL-6     | The high levels of circulating IL-6 found after HFD feeding in mice and in obese subjects promote inflammatory response in WAT | [121,140] |
| RBP4     | RBP4 is increased in metabolically unhealthy obese and contributes to the physiological alterations of obesity, such as insulin resistance and dyslipidemia | [141,142] |
| Myostatin | Inhibiting myostatin signaling increases mitochondrial biogenesis but also insulin resistance | [146–148] |
Box 1: In need of answers

In the last decades, increasing efforts have been made to understand the mechanisms behind tissue communication. Omics approaches have been used to characterize novel molecules participating in inter-organ communication, like Lcn5 and Notum [135], but more research is necessary to understand their role in normal physiology. These novel techniques will allow for the identification of novel players in inter-organ communication, but identifying their receptors/transporters, understanding their mechanism of action, and defining their target cell type(s) will captivate researchers in the field for the years to come.

Additionally, the study of inter-organ interactions in different physiological conditions is of high relevance for the optimization of drug efficiency. Indeed, it is well known that fasting/feeding cycles can influence drug efficiency [172]; however, the mechanism behind this observation remains mostly unknown. Diet composition, nutrient availability and metabolic status can also modulate pharmacological treatments. Therefore, the direct use of specific diets, or the modulation of inter-organ communication, could have a pharmacological effect on its own [167] or increase the efficiency of pharmacological approaches to treat a wide variety of diseases [173,174]. Special efforts must be made to characterize the role of metabolites and lipids as signaling molecules that can potentially act in an autocrine, a paracrine, or an endocrine manner [162]. We also believe that special attention should be placed on exosomes. These small, naturally existing vesicles are the perfect vehicle to transfer molecules from cell to cell and tissue to tissue.

directly modulate cellular metabolic responses not only by acting as substrates for metabolic reactions, but also as signaling molecules by directly activating different signaling pathways via specific membrane receptors [162]. Two recent elegant examples of the importance of metabolites in maintaining energy homeostasis via inter-organ communication were published < 2 years ago. In one instance, Simcox and colleagues showed that upon cold exposure, WAT produces free fatty acids that, in turn, promote hepatic acylcarnitine production. These acylcarnitines are in fine used by BAT for adaptive thermogenesis [163]. In addition, Mills and colleagues demonstrated that succinate accumulates in BAT upon cold exposure and favors thermogenesis in an UCP1-dependent manner [164].

Furthermore, gut microbiota has been described in the past two decades as a very important player in the regulation of whole-body energy homeostasis, in response to diverse stimuli such as cold [165,166], nutrition [167,168], or fasting/feeding cycles [168–170], through the production of mediators such as short chain fatty acids (SCFAs) and secondary BAs [167,169].

Finally, vesicles enabling the transfer of molecules from one tissue to the other may regulate systemic metabolism. Exosomes are such vesicles. More precisely, adipose tissue exosomes carrying circulating miRNAs have recently been shown to have far-reaching effects in other peripheral tissues, and can therefore be considered the most recent family of adipokines [171]. For instance, BAT-produced mir-99b loaded exosomes contribute to the repression of hepatic PGC21 expression [171].

Overall, the findings summarized in this review highlight the importance of inter-organ communication in health and disease. They further suggest that multiple stimuli modifying the expression/secretion, the function, and the targets for potentially thousands of molecules (in a broad sense) that affect whole-body energy metabolism remain to be described/identified.

Acknowledgements

The authors acknowledge all the members of the Fajas laboratory for support and discussions. I.-C. Lopez-Meja is supported by the Swiss National Science Foundation (Ambizione PZ00P3_168077). The work from Prof. Fajas lab is supported by the Swiss National Foundation (31003A_179271) and the University of Lausanne.

Conflict of interest

The authors declare that they have no conflict of interest.

References

1. Dinarello CA (2007) Historical insights into cytokines. Eur J Immunol 37 (Suppl 1): S53–S45
2. Ryan DC, Murphy MP, Frezza C, Prag HA, Chouchani ET, O’Neill LA, Mills EL (2019) Coupling Krebs cycle metabolites to signalling in immunity and cancer. Nat Metab 1: 16–33
3. Myers Jr MG, Olson DP (2012) Central nervous system control of metabolism. Nature 491: 357–363
4. Nogueiras R, Tschop MH, Zigman JM (2008) Central nervous system regulation of energy metabolism: ghrelin versus leptin. Ann N Y Acad Sci 1126: 14–19
5. Bartness TJ, Shrestha YB, Vaughan CH, Schwartz GJ, Song CK (2010) Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol Cell Endocrinol 318: 34–43
6. Bernard C (1853) Nouvelle fonction du foie considéré comme organe producteur de matière sucrée chez l’homme et les animaux. Paris: Bailière JB
7. Bayliss WM, Starling EH (1902) The mechanism of pancreatic secretion. J Physiol 28: 325–353
8. Tata JR (2005) One hundred years of hormones. EMBO Rep 6: 490–496
9. Cori CF, Cori GT (1946) Carbohydrate metabolism. Annu Rev Biochem 15: 193–218
10. Meex RCR, Watt MJ (2017) Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol 13: 509–520
11. Giudice J, Taylor JM (2017) Muscle as a paracrine and endocrine organ. Curr Opin Pharmacol 34: 49–55
12. Fasshauer M, Bluher M (2013) Adipokines in health and disease. Trends Pharmacol Sci 36: 461–470
13. Villarroya F, Cerejo R, Villarroya J, Giralt M (2017) Brown adipose tissue as a secretory organ. Nat Rev Endocrinol 13: 26–35
14. Longo VD, Panda S (2016) Fasting, circadian rhythms, and time-restricted feeding in healthy lifespans. Cell Metab 23: 1048–1059
15. Gnocchi D, Bruscalupi G (2017) Circadian rhythms and hormonal homeostasis: pathophysiological implications. Biology (Basel) 6: 10
16. Betz MJ, Enerback S (2015) Human brown adipose tissue: what we have learned so far. Diabetes 64: 2352–2360
17. Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8: 457–465
18. Rankin LC, Artis D (2018) Beyond host defense: emerging functions of the immune system in regulating complex tissue physiology. Cell 173: 554–567
19. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA et al (2002) Gut
hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650–654
20. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meenan K, Choi SJ, Taylor GM, Heath MM, Lambert PD et al (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69–72
21. Ronveaux CC, Tome D, Raybould HE (2015) Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. J Nutr 145: 672–680
22. Cheng CY, Chu JY, Chow BK (2011) Central and peripheral administration of secretin inhibits food intake in mice through the activation of the melanocortin system. Neuropsychopharmacology 36: 459–471
23. Chu JY, Cheng CY, Sekar R, Chow BK (2013) Vagal afferent mediates the anorectic effect of peripheral secretin. PLoS One 8: e64599
24. Tokarz VL, MacDonald PE, Klip A (2018) The cell biology of systemic insulin function. J Cell Biol 217: 2273–2289
25. Kersten S (2001) Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2: 282–286
26. Vieira E, Salehi A, Gyfle E (2007) Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia 50: 370–379
27. Lee SH, Zabolotny JM, Huang H, Lee H, Kim YB (2016) Insulin in the nervous system and the mind: functions in metabolism, memory, and mood. Mol Metab 5: 589–601
28. Gray SM, Meijer RJ, Barrett EJ (2014) Insulin regulates brain function, but how does it get there? Diabetes 63: 3992–3997
29. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR (2000) Role of brain insulin receptor in control of body weight and reproduction. Science 289: 2122–2125
30. Dodd GT, Michael NJ, Lee-Young RS, Mangiafico SP, Pryor JT, Munder AC, Simonds SE, Bruning JC, Zhang CY, Cowley MA et al (2018) Insulin regulates POMC neuronal plasticity to control glucose metabolism. Elife 7: e38704
31. Dodd GT, Lee-Young RS, Bruning JC, Tiganis T (2018) TCPTP regulates insulin signaling in AgRP neurons to coordinate glucose metabolism with feeding. Diabetes 67: 1246–1257
32. O-Sullivan I, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, DePinho RA, Stolz DB, Kahn CR, Schwartz MW et al (2015) Fox01 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun 6: 7079
33. Titchenell PM, Chu Q, Monks BR, Birnbaum MJ (2015) Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat Commun 6: 7078
34. Obici S, Zhang BB, Karkanas G, Rossetti L (2002) Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8: 1376–1382
35. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS (1995) Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1: 1311–1314
36. Ingalls AM, Dickie MM, Snell GD (1950) Obese, a new mutation in the house mouse. J Hered 41: 317–318
37. Zhang Y, Proença R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the obese mouse gene and its human homologue. Nature 372: 425–432
38. Pan WW, Myers JR MG (2018) Leptin and the maintenance of elevated body weight. Nat Rev Neurosci 19: 95–105
39. Stern JH, Rutkowski JM, Scherer PE (2016) Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab 23: 770–784
40. Minokoshi Y, Kim YB, Peroni OD, Frigeri LG, Muller C, Carling D, Kahn BB (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: 339–343
41. D’Souza AM, Neumann UH, Giavas MM, Kieffer TJ (2017) The glucose-regulatory actions of leptin. Mol Metab 6: 1052–1065
42. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA et al (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217–225
43. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliwer SA, Mangelsdorf DJ (2011) FGF19 as a post-prandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331: 1621–1624
44. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN et al (2011) FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 13: 729–738
45. Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ (2013) Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154: 9–15
46. Picard A, Soyer J, Berney X, Tarussio D, Quenneville S, Jan M, Grousson-M, Burdet F, Ibberson M, Thorens B (2016) A genetic screen identifies hypothalamic Fgf15 as a regulator of glucagon secretion. Cell Rep 17: 1795–1806
47. Ge X, Yang H, Bednarek MA, Galon-Tilleman H, Chen P, Chen M, Lichtman JS, Wang Y, Dalmas O, Yin Y et al (2018) LEAP2 is an endogenous antagonist of the ghrelin receptor. Cell Metab 27: 461–469 e6
48. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714–1719
49. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656–660
50. Al Massadi O, Lopez M, Tschop M, Dieguez C, Nogueiras R (2017) Current understanding of the hypothalamic ghrelin pathways inducing appetite and adiposity. Trends Neurosci 40: 167–180
51. Chuang JC, Sakata I, Kono D, Perello M, Osborne-Lawrence S, Repa JJ, Zigman JM (2011) Ghrelin directly stimulates glucagon secretion from pancreatic alpha-cells. Mol Endocrinol 25: 1600–1611
52. Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407: 908–913
53. Theander-Carrillo C, Wiedem P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger P, Castaneda TR, Muzzin P, Schurrmann A, Szanto I et al (2006) Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116: 1983–1993
54. Jackson MB, Ahima RS (2006) Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci (Lond) 110: 143–152
55. Steinberg GR, Kemp BE (2007) Adiponectin: starving for attention. Cell Metab 6: 3–4
56. Kubota N, Yano W, Kubota T, Yamauchi T, Itah S, Kumagai H, Kozono H, Takamoto I, Okamoto S, Shiuchi T et al (2007) Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6: 55–68
57. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM et al (2012) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17: 55–63

58. Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, Kobayashi M, Iwane A, Sasaki T, Okazaki Y et al (2011) Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 13: 401–412

59. Romere C, Duerraschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B et al (2016) Asprosin, a fasting-induced glucogenic protein hormone. Cell 165: 566–579

60. Duerraschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M et al (2017) Asprosin is a centrally acting orexigenic hormone. Nat Med 23: 1444–1453

61. Khantonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyer JS, Owens RA et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627–1635

62. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5: 426–437

63. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V et al (2007) Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 5: 415–425

64. BonDurant LD, Potthoff MJ (2018) Fibroblast growth factor 21: a versatile regulator of metabolic homeostasis. Annu Rev Nutr 38: 173–196

65. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Klevwer SA et al (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 106: 10853–10858

66. Lamy CM, Sanno H, Labouebe G, Picard A, Magnan C, Chatton JY, Thorens B (2014) Hypoglycemia-activated GLUT2 neurons of the nucleus tractus solitarius stimulate vascular activity and glucagon secretion. Cell Metab 19: 527–538

67. Garretson JT, Szymanski LA, Schwartz GJ, Xue B, Ryu V, Bartness TJ (2016) Lipolysis sensation by white fat afferent nerves triggers brown fat thermogenesis. Mol Metab 5: 626–634

68. Geerling JJ, Boon MR, Kooijman S, Parlevliet ET, Havekes LM, Romijn JA, Meurs IM, Rensen PC (2014) Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent studies. Lipid Res 55: 180–189

69. Zeng W, Pirzgalska RM, Pereira MM, Kubasova N, Barateiro A, Seixas E, Lu YH, Kozlova A, Voss H, Martins GG et al (2015) Sympathetic neuro-adipose connections mediate leptin-driven lipolysis. Cell 163: 84–94

70. Chi J, Wu Z, Choi CHJ, Nguyen L, Tegegne S, Ackerman SE, Crane A, Marchilod F, Tesser-Lavigne M, Cohen P (2018) Three-dimensional adipose tissue imaging reveals regional variation in beige fat biogenesis and PRDM16-dependent sympathetic neurite density. Cell Metab 27: 226–236 e3

71. Jiang H, Ding X, Cao Y, Wang H, Zeng W (2017) Dense intra-adipose sympathetic arborizations are essential for cold-induced browning of mouse white adipose tissue. Cell Metab 26: 686–692 e3

72. Zhu Y, Gao Y, Tao C, Shao M, Zhao S, Huang W, Yao T, Johnson JA, Liu T, Cypress AM et al (2016) Connexin 43 mediates white adipose tissue beiging by facilitating the propagation of sympathetic neuronal signals. Cell Metab 24: 420–433

73. Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84: 277–359

74. Gesta S, Tseng YH, Kahn CR (2007) Developmental origin of fat: tracking obesity to its source. Cell 131: 242–256

75. Cypress AM, Kahn CR (2010) Brown fat as a therapy for obesity and diabetes. Curr Opin Endocrinol Diabetes Obes 17: 143–149

76. Zhang W, Bi S (2015) Hypothalamic regulation of brown adipose tissue thermogenesis and energy homeostasis. Front Endocrinol (Lausanne) 6: 136

77. Sellayah D, Bharaj P, Siddker D (2011) Orexin is required for brown adipose tissue development, differentiation, and function. Cell Metab 14: 478–490

78. Monda M, Viggiano AN, Viggiano A, Viggiano E, Lanza A, De Luca V (2005) Hyperthermic reactions induced by orexin A: role of the ventromedial hypothalamus. Eur J Neurosci 22: 1169–1175

79. Martins L, Seoane-Collazo P, Contreras C, Gonzalez-Garcia L, Nogueiras R et al (2016) A functional link between AMPK and orexin mediates the effect of BMPβB on energy balance. Cell Rep 16: 2231–2242

80. Whittle AJ, Carobbio S, Martins L, Slawik M, Hondares E, Vazquez MJ, Morgan D, Cisakisz RL, Gallego R, Rodriguez-Cuenca S et al (2012) BMPβB increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 149: 871–885

81. Zaretskaia MV, Zaretsky DV, Shekhar A, DiMicco JA (2002) Chemical stimulation of the dorsomedial hypothalamic evokes non-shivering thermogenesis in anesthetized rats. Brain Res 928: 113–125

82. Lee SJ, Sanchez-Watts G, Krieger JP, Pignolosa A, Moren PN, Cortella A, Petterssen KG, Vrdoljak D, Hayes MR, Kanoski SE et al (2018) Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity. Mol Metab 11: 33–46

83. Murano I, Barbatelli G, Giordano A, Cinti S (2009) Noradrenergic parenchymal nerve fiber branching after cold acclimatization correlates with brown adipocyte density in mouse adipose organ. J Anat 214: 171–178

84. Bartness TJ, Vaughan CHG, Song CK (2010) Sympathetic and sensory innervation of brown adipose tissue. Int J Obes (Lond) 34(Suppl 1): S36–S42

85. Fedorenko A, Ichikawa PV, Kirschhok Y (2012) Mechanism of fatty-acid–dependent UCPI uncoupling in brown fat mitochondria. Cell 151: 400–413

86. Obregon MJ (2014) Adipose tissues and thyroid hormones. Front Physiol 5: 479

87. Brent GA (2012) Mechanisms of thyroid hormone action. J Clin Invest 122: 3035–3043

88. Bianco AC, McAninch EA (2013) The role of thyroid hormone and brown adipose tissue in energy homeostasis. Lancet Diabetes Endocrinol 1: 250–258

89. Christofforeta MA, Linardi CC, de Jesus L, Ebina KN, Carvalho SD, Ribeiro MO, Rabelo R, Curcio C, Martins L, Kimura ET et al (2004) Mice with targeted disruption of the Dio2 gene have cold-induced overexpression of the uncoupling protein 1 gene but fail to increase brown adipose tissue lipogenesis and adaptive thermogenesis. Diabetes 53: 577–584

90. Wu J, Cohen P, Spiegelman BM (2013) Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev 27: 234–250
91. Hondarese E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, Villarroya F (2011) Thermogenic activation induces FGF21 expression and release in brown adipose tissue. *J Biol Chem* 286: 12983–12990

92. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, Wu J, Khartonovkova A, Flier JS, Maratos-Flier E et al (2012) FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. *Genes Dev* 26: 271 – 281

93. Keipert S, Kutschke M, Ost M, Schwarzmayr T, van Schothorst EM, Lamp D, Brachthauser L, Hamp I, Mazibuko SE, Hartwig S et al (2017) Long-term cold adaptation does not require FGF21 or UCP1. *Cell Metab* 26: 437 – 446 e5

94. Veniant MM, Sivits G, Helmering j, Komorowski R, Lee J, Fan W, Moyer C, Lloy D (2015) Pharmacologic effects of FGF21 are independent of the “browning” of white adipose tissue. *Cell Metab* 21: 731 – 738

95. Ameka M, Markan KR, Morgan DA, BonDurant LD, Idiga SO, Naber MC, Zhu Z, Zingman LV, Grobe JL, Rahmouni K et al (2019) Liver derived FGF21 maintains core body temperature during acute cold exposure. *Sci Rep* 9: 630

96. Worthmann A, John C, Ruhlemann MC, Baguhl M, Heinsen FA, Saltenberg N, Heine M, Schlein C, Evangelakos I, Mineo C et al (2017) Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. *Nat Metab* 23: 839 – 849

97. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T et al (2008) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature* 439: 484 – 489

98. Velazquez-Villegas LA, Perino A, Lemos V, Zietak M, Nomura M, Pols TWH, Schoonjans K (2018) TGRS signaling promotes mitochondrial fission and beige remodelling of white adipose tissue. *Nat Commun* 9: 245

99. Long JZ, Roche AM, Berdan CA, Louie SM, Roberts AJ, Svensson KJ, Dou FY, Bateman LA, Mina Al, Deng Z et al (2018) Ablation of PM20D1 reveals N-acetyl amino acid control of metabolism and nociception. *Proc Natl Acad Sci USA* 115: E6979–E6945

100. Long JZ, Svensson KJ, Bateman LA, Lin H, Kamenecka T, Lokurkar IA, Lou J, Rao RR, Chang MR, Jedrychowski MP et al (2016) The secreted enzyme PM20D1 regulates lipidated amino acid uncouplers of mitochondria. *Cell* 166: 424 – 435

101. Glick Z (1982) Inverse relationship between brown fat thermogenesis and meal size: the thermostatic control of food intake revisited. *Physiol Behav* 29: 1137 – 1140

102. Ud M, Saari T, Raiko J, Kudomi N, Maurer SF, Lahesmaa M, Fromme T, Amini EZ, Klingenspor M, Solin O et al (2018) Postprandial oxidative metabolism of human brown fat indicates thermogenesis. *Cell Metab* 28: 207 – 216 e3

103. Saito M (2013) Brown adipose tissue as a regulator of energy expenditure and body fat in humans. *Diabetes Metab J* 37: 22 – 29

104. Kelsey R (2018) BAT is involved in control of satiation. *Nat Rev Endocrinol* 15: 1

105. Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, Serrano M, Ferno J, Salvador J, Escalada j et al (2014) GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. *Diabetes* 63: 3346 – 3358

106. Blouet C, Schwartz Cj (2012) Duodenal lipid sensing activates vagal afferents to regulate non-shivering brown fat thermogenesis in rats. *PloS One* 7: e51898

107. Li Y, Schnabl K, Cablier SM, Willershauser M, Reber J, Karlas A, Laurila S, Lahesmaa M, U Din M, Bast-Habersbrunner A et al (2018) Secretin-activated brown fat mediates prandial thermogenesis to induce satiation. *Cell* 175: 1561 – 1574 e12

108. Dodd GT, Decherf S, Loh K, Simonds SE, Wiede F, Balland E, Merry TL, Munzberg H, Zhang ZY, Kahn BB et al (2015) Leptin and insulin act on POMC neurons to promote the browning of white fat. *Cell* 160: 88 – 104

109. Dodd GT, Andrews ZB, Simonds SE, Michael NJ, DeVeer M, Bruning JC, Spanswick D, Cowley MA, Tiganis T et al (2017) A hypothalamic phosphatase switch coordinates energy expenditure with feeding. *Cell Metab* 26: 375 – 393 e7

110. Febbraio MA (2017) Exercise metabolism in 2016: health benefits of exercise – more than meets the eye!. *Nat Rev Endocrinol* 13: 72 – 74

111. Goldstein MS (1961) Humoral nature of the hypoglycemic factor of muscular work. *Diabetes* 10: 232 – 234

112. Hoffmann C, Wieght C (2017) Skeletal muscle as an endocrine organ: the role of myokines in exercise adaptations. *Cold Spring Harb Perspect Med?*: a029793

113. Petersen AM, Petersen BK (2005) The anti-inflammatory effect of exercise. *J Appl Physiol* (1985) 98: 1154 – 1162

114. Leal LG, Lopes MA, Batista Jr ML (2018) Physical exercise-induced myokines and muscle-adipose tissue crosstalk: a review of current knowledge and the implications for health and metabolic diseases. *Front Physiol* 9: 1307

115. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ et al (2012) A PGC-1alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature* 481: 463 – 468

116. Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, Qi L, Zhang M, Wang X, Cui T et al (2014) Insulin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. *Diabetes* 63: 514 – 525

117. Perakakis N, Triantafyllopou LA, Fernandez-Real JM, Huy JY, Park KH, Seufert J, Mantzoros CS (2017) Physiology and role of irisin in glucose homeostasis. *Nat Rev Endocrinol* 13: 324 – 337

118. Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C, Perron RM, Werner CD, Phan QG, Kammula US et al (2014) Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. *Cell Metab* 19: 302 – 309

119. Lourenco MV, Frozza RL, de Freitas GB, Zhang H, Kincheski GC, Ribero FC, Goncalves RA, Clarke JR, Beckman D, Staniszewski A et al (2019) Exercise-linked FNDCS/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. *Nat Med* 25: 165 – 175

120. Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Belen Crujeiras A, Seoane LM, Casanueva FF, Pardo M (2013) FNDCS/irisin is not only a myokine but also an adipokine. *PloS One* 8: e60563

121. Fiuza-Luces C, Santos-Lozano A, Clarke JR, Beckman D, Staniszewski A et al (2019) Exercise-linked FNDCS/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. *Nat Med* 25: 165 – 175

122. Moon HY, Becke A, Berron D, Becker B, Sah N, Benoni G, Janke E, Lubejko ST, Greig NH, Mattison JA et al (2016) Running-induced systemic cathespin B secretion is associated with memory function. *Cell Metab* 24: 332 – 340

123. Virtanen KA (2014) BAT thermogenesis: linking shivering to exercise. *Cell Metab* 19: 352 – 354

124. Auldiss P, Betts J, Sale C, Pope M, Budge H, Symonds ME (2018) Exercise-induced ‘browning’ of adipose tissues. *Metabolism* 81: 63 – 70
The Authors

Judit Castillo-Armengol et al

EMBO reports

20. e47903 | 2019

125. Suzuki WA (2016) How body affects brain. Cell Metab 24: 192 – 193

126. Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106: 473 – 481

127. Munzberg H, Flier JS, Bjorbaek C (2004) Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 145: 4880 – 4889

128. Ballard E, Chen W, Dodd GT, Conductier C, Coppari R, Tiganis T, Cowley MA (2019) Leptin signaling in the arcuate nucleus reduces insulin’s capacity to suppress hepatic glucose production in obese mice. Cell Rep 26: 346 – 355 e3

129. Shi YC, Lau J, Lin Z, Zhang H, Zhai L, Sperk G, Heilbronn LK, Mietzsch M, Balland E, Chen W, Dodd GT, Conductier G, Coppari R, Tiganis T, Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Walsh SA, Ornitz DM, Potthoff MJ (2018) A strategy for brown fat activators. J Biol Sci Med Sci 64: 940 – 948

130. Okada-Iwabu M, Yamauchi T, Iwabu M, Kimura-Someya T, Shirouzu M, Matsuda K, Yamaguchi M, Tanabe H, Zhang H, Zhai L, Sperk G, Heilbronn LK, Mietzsch M, Balland E, Chen W, Dodd GT, Conductier G, Coppari R, Tiganis T, Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Walsh SA, Ornitz DM, Potthoff MJ (2018) A small-molecule AdipoRon agonist for type 2 diabetes and short life in obesity. Nature 503: 493 – 499

131. Q Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS (2014) Adiponectin acts in the brain to decrease body weight. Nat Med 10: 524 – 529

132. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, Bauer SM, Wade M, Singhal E, Cheng CC et al (2013) An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 17: 790 – 797

133. BonDurant LD, Ameke M, Naber MC, Markan KD, Idiga SO, Acevedo MR, Walsh SA, Ornitz DM, Pothoff MJ (2017) FGF21 regulates metabolism through adipose-dependent and -independent mechanisms. Cell Metab 25: 955 – 964 e4

134. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonov KA, Flier JS, Maratos-Flier E (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59: 2781 – 2789

135. Seldin MM, Koplev S, Rajbandari P, Vergnes L, Rosenberg GM, Meng Y, Pan C, Phuong TMN, Gharakhani R, Chen N et al (2018) A strategy for discovery of endocrine interactions with application to whole-body metabolism. Cell Metab 27: 1138 – 1155 e6

136. Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, Jedrychowski MP, Ruas JL, Wrann CD, Lo JC et al (2014) Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell 157: 1279 – 1291

137. Lee JH, Kang YE, Kim JM, Choi M, Joong HK, Kim HJ, Ku BJ (2018) Serum Meteorin-like protein levels decreased in patients newly diagnosed with type 2 diabetes. Diabetes Res Clin Pract 135: 7 – 10

138. Briggs DI, Enriollo P, Lemus MB, Cowley MA, Andrews ZB (2010) Diet-induced obesity causes ghlrelin resistance in arcuate NPY/AgRP neurons. Endocrinology 151: 4745 – 4755

139. Madsbad S (2014) The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab 16: 9 – 21

140. Kraakman MJ, Kamoun HL, Allen TL, Desvaucelle V, Henstridge DC, Estevez E, Matthews VB, Neil B, White DA, Murphy AJ et al (2015) Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab 21: 403 – 416

141. Yang Q, Graham TE, Mody N, Pretner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356 – 362

142. Graham TE, Yang Q, Bluhm M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason C, Oberbach A, Jansson PA, Smith U et al (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354: 2522 – 2526

143. McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83 – 90

144. Argiles JM, Orpi M, Busquets S, Lopez-Soriano FJ (2012) Myostatin: more than just a regulator of muscle mass. Drug Discov Today 17: 702 – 709

145. LeBrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM, Brown TA (2009) Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 64: 940 – 948

146. Zhao B, Wall RJ, Yang J (2005) Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance. Biochem Biophys Res Commun 337: 248 – 255

147. Shan T, Liang X, Bi P, Kuang S (2013) Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1alpha-Fndc5 pathway in muscle. FASEB J 27: 1981 – 1989

148. Zhang C, McFarlane L, Kokkody V, Bonala S, Ge X, Masuda S, Gluckman PD, Sharma M, Kambadur R (2011) Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia 54: 1491 – 1501

149. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282: 1568 – 1575

150. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA (2000) Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 85: 4003 – 4009

151. Villarroya F, Vidal-Puig A (2013) Beyond the sympathetic tone: the new brown fat activators. Cell Metab 17: 638 – 643

152. Zhang C, Huang Z, Gu J, Yan X, Lu X, Zhou S, Wang S, Shao M, Zhang F, Peng P et al (2015) Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetesologia 58: 1937 – 1948

153. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivitz V, Vonderfecht S, Hecht R, Li YS, Lindberg RA et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250 – 259

154. Gaich G, Chien YF, Hu G, Glass LC, Deeg MA, Holland W, Kharitonov A, Bumol T, Schilske HK, Moller DE (2013) The effects of LY2405319, an FGF21 analog, on obese human subjects with type 2 diabetes. Cell Metab 18: 333 – 340

155. Kharitonov A, Adams AC (2014) Inventing new medicines: the FGF21 story. Mol Metab 3: 221 – 229

156. Wei W, Dutschak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R, Mohammadi M, Gerard RD, Dechow PC et al (2012) Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci USA 109: 3143 – 3148

157. Andersen A, Lund A, Knop FK, Vilsboll T (2018) Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 14: 390 – 403

158. Seghieni M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsboll T (2018) Future perspectives on GLP-1 receptor agonists and GLP-1/
glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne) 9: 649

159. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwhelen M, Kampf C, Wester K, Hober S et al (2010) Towards a knowledge–based Human Protein Atlas. Nat Biotechnol 28: 1248–1250

160. Lindskog C (2015) The potential clinical impact of the tissue-based map of the human proteome. Expert Reu Proteomics 12: 213–215

161. Cerejo R, Gavaldá-Navarro A, Cairo M, Quesada-Lopez T, Villarroya J, Moron-Ros S, Sanchez-Infantes D, Peyrou M, Iglesias R, Mampel T et al (2018) CXCL14, a brown adipokine that mediates brown-fat-to-macrophage communication in thermogenic adaptation. Cell Metab 28: 750–763 e6

162. Yang Q, Vijayakumar A, Kahn BB (2018) Metabolites as regulators of insulin sensitivity and metabolism. Nat Rev Mol Cell Biol 19: 654–672

163. Simcox J, Geoghegan G, Maschek JA, Bensard CL, Pasquali M, Miao R, Lee S, Jiang L, Huck I, Kershaw EE et al (2017) Global analysis of plasma lipids identifies liver-derived acylcarnitines as a fuel source for brown fat thermogenesis. Cell Metab 26: 509–522 e6

164. Mills EL, Pierce KA, Jedrychowski MP, Garrity R, Winther S, Vidoni S, Yoneshiro T, Spinelli JB, Lu GZ, Kazak L et al (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560: 102–106

165. Chevalier C, Stojanovic O, Colin Dj, Suarez-Zamorano N, Tarallo V, Veyrat-Durebeix C, Rigo D, Fabbiano S, Stevanovic A, Hagemann S et al (2015) Gut microbiota orchestrates energy homeostasis during cold. Cell 163: 1360–1374

166. Li B, Li L, Li M, Lam SM, Wang G, Wu Y, Zhang H, Niu C, Zhang X, Liu X et al (2019) Microbiota depletion impairs thermogenesis of brown adipose tissue and browning of white adipose tissue. Cell Rep 26: 2720–2737 e5

167. Trompette A, Gollwitzer ES, Patarroni C, Lopez-Mejia IC, Riva E, Pernot J, Ubags N, Fajas L, Nicod LP, Marsland BJ (2018) Dietary fiber confers protection against flu by shaping Ly6c(−) patrolling monocyte hematopoiesis and CD8(+) T cell metabolism. Immunity 48: 992–1005 e8

168. Zmora N, Suez J, Elinav E (2019) You are what you eat: diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol 16: 35–56

169. Cani PD, Van Hul M, Lefort C, Depommier C, Rastelli M, Everard A (2019) Microbial regulation of organismal energy homeostasis. Nat Metab 1: 34–46

170. Li G, Xie C, Lu S, Nichols RG, Tian Y, Li L, Patel D, Ma Y, Brocker CN, Yan T et al (2017) Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. Cell Metab 26: 801

171. Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, Wolfrum C, Rao TN, Winnay JN, Garcia-Martin R, Grinspoon SK et al (2017) Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 542: 450–455

172. Charman WN, Porter CJ, Mithani S, Dressman JB (1997) Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86: 269–282

173. Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR et al (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560: 499–503

174. Quail DF, Olson OC, Bhaward P, Walsh LA, Akkari L, Quick ML, Chen IC, Wendel N, Ben-Chetrit N, Walker J et al (2017) Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through ILS and GM-CSF. Nat Cell Biol 19: 974–987

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.